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Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversity set of
1.8 million compounds was screened against the three kinetoplastids most relevant to human disease, i.e.
Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Secondary confirmatory and
orthogonal intracellular anti-parasiticidal assays were conducted, and the potential for non-specific
cytotoxicity determined. Hit compounds were chemically clustered and triaged for desirable
physicochemical properties. The hypothetical biological target space covered by these diversity sets was
investigated through bioinformatics methodologies. Consequently, three anti-kinetoplastid chemical boxes
of,200 compounds each were assembled. Functional analyses of these compounds suggest a wide array of
potential modes of action against kinetoplastid kinases, proteases and cytochromes as well as potential host–
pathogen targets. This is the first published parallel high throughput screening of a pharma compound
collection against kinetoplastids. The compound sets are provided as an open resource for future lead
discovery programs, and to address important research questions.
H
alf a billion people are at risk of contracting diseases caused by kinetoplastid parasites of the genera
Leishmania and Trypanosoma1. This group of flagellated protozoans causes African trypanosomiasis
(T. brucei), Chagas disease (T. cruzi) and various clinical manifestations of leishmaniasis (Leishmania
spp.). In particular, L. donovani and L. infantum are responsible for life-threatening visceral leishmaniasis. An
estimated 20 million individuals are infected with kinetoplastid pathogens, resulting in extensive suffering and
around 95,000 deaths per year1. Despite this considerable disease burden, effective drug treatments for these
parasites are lacking or inadequate and new therapies are required2,3.
Although these protozoans are transmitted by different insects and the human diseases they cause are clinically
distinctive, much of their molecular and cellular biology is similar1. They are defined by the presence of a DNA-
containing region, the ‘kinetoplast’, in their single large mitochondrion; have similar genomic organization and
cellular structures (e.g. a single flagellum for motion, and glycosomes); and undergo morphological changes
during their life cycles in the insect and vertebrate hosts. The genome of each parasite exceeds 8,000 genes, more
than 6,000 being common orthologs4. Analysis of the genomes of L. major, T. cruzi and T. brucei (known as
TriTryp) has revealed many common core metabolic functions as well as pathways that might reflect specific
adaptations to environments within their insect and vertebrate hosts4. Strikingly, approximately 50% of these
genomes encode for hypothetical proteins that do not resemble orthologs in the human genome1. In addition,
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several human protein classes are not represented in kinetoplastid
genomes, e.g. no orthologs have been found for tyrosine kinases5.
These differences suggest that there may be essential proteins that
can be exploited as selective targets for chemotherapy.
This paper reports the application of whole-cell phenotypic assays
against L. donovani, T. cruzi andT. brucei to screen the GlaxoSmithKline
HTS diversity set of 1.8 million compounds. This is the first parallel
HTS program which has been disclosed for any pharma compound
set against the three kinetoplastids most relevant to human disease.
Three kinetoplastid chemical boxes have been assembled and all data
are publically available to encourage research and drug discovery
efforts in combating these devastating infections.
Results
High throughput screening (HTS) campaigns and hit identification.
The 1.8 million GlaxoSmithKline HTS screening collection was
tested against L. donovani, T. cruzi and T. brucei between October
2012-May 2014 using a primary whole-cell phenotypic screen as
described in the Methods. All compounds were tested at a final
assay concentration of 5 mM in the L. donovani and T. cruzi
assays and at 4.2 mM in the T. brucei assays. Primary hits were
identified using algorithms developed in-house6. For each of the
three phenotypic (primary) screens, one corresponding orthogonal
assay was conducted to prove genuine activity and help to rule out
false activity caused by assay interference. HTS campaigns are
described in Supplementary Table 1, HTS results are summarized
in Supplementary Figure 1 and the HTS progression cascade in
Supplementary Figure 2.
Leishmania donovani. Growth inhibition of free-living L. donovani
amastigotes in axenic cultures was determined in an assay adapted
from de Ryker, et al.7. At an average statistical cut-off of .30%,
67,400 primary hits were identified; an overall hit rate of 4%.
Using the same assay, confirmatory activity above the cut-off in at
least one replicate was displayed for 32,200 compounds. These
remaining compounds were tested in an intracellular assay of L.
donovani-infected THP1-derived macrophages8. The cut-off obtained
using the amastigotes per macrophage output was .34% and the
corresponding hit confirmation rate was 31%, resulting in ca. 5,500
active compounds selective for L. donovani over macrophage cells.
Using physicochemical parameters9, such as molecular weight.500
Da, calculated Property Forecast Index (cPFI), 8, and,5 aromatic
rings, the number of hits was reduced to 4,700. Compound potency
(pIC50) was determined in a dose–response experiment and acute
cytotoxicity of the compounds was assessed using the HepG2 assay
(see Methods). Consequently, 351 non-cytotoxic anti-L. donovani
compounds were identified.
Trypanosoma cruzi. Growth inhibition was determined using NIH-
3T3 fibroblasts infectedwith a recombinantT. cruzi strain expressing
beta-galactosidase as an intracellular reporter, as adapted from
Bettiol, et al.10. The average statistical cutoff was .27% inhibition
and the obtained overall hit rate was 7.7%, i.e. 130,678 active com-
pounds. This list was reduced to 45,100 compounds by increasing the
cut-off for biological response to.45%, excluding compounds with
historical annotation in GSK databases for cytotoxicity versus the
HepG2 cell line (pIC50 . 6), and including only those compounds
with sub-mM IC50 values, cPFI , 8, and aromatic rings , 4.
Duplicate confirmation experiments were performed plus an inter-
ference assay against the host cell (i.e. NIH-3T3 fibroblasts). Based
on.70% inhibition in the T. cruzi assay and,25% in the NIH-3T3
interference assay, 3,985 compounds were selected for dose–res-
ponse and tested in parallel in the primary T. cruzi assay, the 3T3
host cell interference assay and for cytotoxicity against HepG2. A
total of 2,310 compounds were identified with a T. cruzi pIC50 . 5
and a selectivity index . 10. These compounds were tested in an
intracellular imaging assay in H9c2 cells (rat cardiomyoctes)11. Also,
because sterol 14a-demethylase (CYP51) inhibitors have known
activity against T. cruzi12, hits were triaged based on T. cruzi
CYP51 inhibition data obtained using a recently developed assay13.
Compounds without CYP51 activity or a selectivity index. 10 for T.
cruzi versusCYP51 were first selected. CYP51 inhibitors with a lower
index were selected only if highly potent against T. cruzi (pIC50. 6).
Overall, these investigations identified 500 non-cytotoxic anti-T.
cruzi compounds.
Trypanosoma brucei. A resazurin fluorescent T. brucei whole-cell
viability assay was used, derived from Sykes & Avery14. An average
cut-off value of.40% resulted in 27,600 hits; a 1.5% overall hit rate.
Confirmatory screening identified 15,200 compounds displaying a
response above cut-off in at least one duplicate. A total of 4,200
compounds were selected for dose–response studies based on
.80% growth inhibition in the confirmation step, cPFI , 8, aro-
matic rings , 5, molecular weight , 500 Da, and in silico deter-
mination of potential CNS penetration15. As well as the primary
assay, these compounds were screened against T. brucei using an
orthogonal ATP-based luminescence assay16, and acute cytotoxicity
was evaluated against HepG2. Based on a pIC50. 6 and selectivity.
10, there were 700 non-cytotoxic anti-T. brucei compounds
identified.
Anti-kinetoplastid chemical boxes. Selection of representative
chemical boxes for the three kinetoplastids started from the most
potent, specific, and non-cytotoxic compounds in the dose–response
outputs of each screen after having filtered for lead-like properties as
described in the Methods. In order to generate representative boxes
with high chemical diversity and potency, compounds were clustered
initially by similarity using a complete-linkage algorithm17, and a
threshold of 0.55. Secondly, they were sorted by decreasing
potency (i.e. pIC50). Compounds were then selected so that all the
clusters were represented in the final ranked boxes by no more than
two members with the highest potency. The final boxes contained
592 compound entries; 192 were active against L. donovani (Leish-
Box), 222 against T. cruzi (Chagas-Box) and 192 against T. brucei
(HAT-Box) (Figure 1, Supplementary Table 2 and available at http://
ebi.ac.uk/chemblntd). The three anti-kinetoplastid chemical boxes
showed little overlap, pointing to specific mechanisms of growth
inhibition or structural divergence across molecular targets in each
parasite. Three compounds were in both the Leish-Box and Chagas-
Box, nine in both the Chagas-Box and HAT-Box and one compound
was present in all three chemical boxes.
Biological profiling and chemical characterization. Database
searches in ChEMBL showed that 88% of compounds in the three
chemical boxes were not previously published. The literature
annotation for the remaining 12% of compounds was unrelated to
activity against Leishmania or Trypanosoma. Furthermore, these
kinetoplastid chemical boxes do not contain analogs (Tanimoto
coefficient . 0.7) to drugs currently used in the clinic for
leishmaniasis, Chagas disease or sleeping sickness. Thus, they
represent highly novel chemical diversity for potential starting
points in drug discovery for kinetoplastid anti-parasitic agents.
Only five compounds were natural products; a similar proportion
to the screening collection.
There was no correlation between compound potency as deter-
mined by the axenic versus intracellular L. donovani assays
(Supplementary Figure 3a). One explanation is that, in the intracel-
lular assay, the compound must pass through two host cell mem-
branes (i.e. plasma membrane and phagolysosome) plus the parasite
cell membrane7, whereas in the axenic assay only the parasite mem-
brane must be crossed. Also, there are significant pH changes from
the extracellular media (acidic in the axenic assay, neutral in the
intra-macrophage assay) to cytosol (neutral) to the parasitophorous
vacuole (acidic pH 5.4). A reduced metabolism within the host cell
www.nature.com/scientificreports
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may also impair drug activity against intra-macrophage L. donovani
amastigotes, and these are slow-replicating, compared to axenic
amastigotes7. In contrast, for T. cruzi and T. brucei there was good
correlation for compound potency between the primary and ortho-
gonal assays (Supplementary Figure 3b, 3c). This is as expected
because the biological system for the assay differs only in the readout
(i.e. fluorescent reporter versus imaging in T. cruzi and fluorescent-
resazurin versus luminescent-ATP in T. brucei) or the host cell (i.e.
NIH-3T3 fibroblasts versus H9c2 cardiomyocytes in T. cruzi).
As mentioned previously, the preclinical and clinical pipeline for
Chagas disease is already well populated with CYP51 inhibitors12. In
the Chagas-box, 42% of compounds represented a sub-set that was
clearly differentiated from the overall compound population, exhibiting
a pIC50 . 6 in both biochemical CYP51 and cellular anti-T. cruzi
imaging assays (Supplementary Figure 4). These compounds may be
flagged as putative CYP51-targeting hits. Conversely, 44% of com-
pounds were CYP51-inactive; the remaining 14% poorly active.
The two imaging assays employed to determine compound activ-
ity against intracellular L. donovani and T. cruzi allowed simultan-
eous measurement of the number of amastigotes and infected cells as
a dual assay readout. Interestingly, compounds in the Leish-Box and
Chagas-Box showed good correlations between both anti-parasitic
readouts, indicating parasite eradication (Supplementary Figure 5).
The screening methods and selection processes produced rela-
tively small shifts in the distributions of clogP and molecular weight
towards higher values, in many cases not significant (Supplementary
Figure 1 | Distribution of potency by chemical box (Leishmania donovani in pink, Trypanosoma brucei in blue and T. cruzi in green) and parasite. Left
panels: 3D scatter plot of pIC50 values for each compound against L. donovani (Ld pIC50, as inhibition of amastigotes per macrophage readout from
imaging assay), T. cruzi (Tc pIC50, as inhibition of amastigotes per cell readout from imaging assay) and T. brucei (Tb pIC50, as inhibition of FLINT from
fluorescent assay). Right panels: Distribution of potency for all compounds of each of the three chemical boxes (,200 compounds distributed into 40
potency bins).
www.nature.com/scientificreports
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Figure 6a, b) (Student t-test for means, data not shown). For the
number of aromatic rings, the distributions were centered at 3 rings;
none of the compounds had .4 aromatic rings (Supplementary
Figure 6c). As expected from the guided triage process, most com-
pounds lie in appropriate lead-like space18.
Discussion: modes of action hypotheses
To assist target identification efforts, we used historical GSK screen-
ing data to generate modes of action hypotheses for the compounds
in the three kinetoplastid chemical boxes. Based on conservative
thresholds (i.e. overall pXC50 $ 5.0, see Methods) for agonist or
antagonist assays, compounds were associated with human protein
targets which were used as BLASTP queries against the respective
parasite genome19. The number of compounds meeting target spe-
cificity criteria was similar across L. donovani (80 compounds) and
T. brucei (82 compounds) but lower for T. cruzi (46 compounds)
(Figure 2).
‘Kinase’ was the most frequent target class (Table 1). A range of
human kinase inhibitor chemotypes were present in the three boxes,
including common hinge binding motifs such as pyrimidines, pyr-
rolopyrimidines, azaindoles, and benzimidazoles. Kinase inhibitors
are a potentially important novel class of anti-kinetoplastid thera-
peutics because of high chemotype diversity in pharmaceutical com-
pound collections and their potency in disrupting parasite survival20.
Compared to the human genome which encodes over 450 kinases21,
the kinomes of Leishmania and Trypanosoma sp. are less diverse,
having ,200 protein kinases5. Kinome-wide RNAi screens of T.
brucei suggest that at least 43 kinases have essential roles in cell cycle
and differentiation by in vitro culture analysis22, and others might
prove to be essential only when tested in vivo. Several putative T.
brucei kinase targets have had cell death or arrest phenotypes
reported in kinome-wide RNAi knock-down experiments22.
Although kinome-wide RNAi studies have not been published for
L. donovani and T. cruzi, kinase inhibitors have activity against L.
donovani in vitro23. The present compound set might be interacting
with 34–40 serine/threonine kinases, depending upon the parasite.
A phylogenetic tree of the entire complement of human and T.
brucei protein kinases was constructed (Figure 3), with additional
annotations for those kinases with reported growth defects22. Several
T. brucei kinases with cell death or arrest phenotypes cluster with
human kinases which alsomet our historical assay specificity criteria,
including aurora kinases (AURK), CDK, CSNK1/2, MAP3K, PIM/
CHEK, and PRKAA. Some kinases are potential drug targets, such as
AURKwhich are known to be involved in cell cycle progression, exist
as single copy genes in kinetoplastids24 and have small molecule
inhibitors with in vitro activity against T. brucei, and L. major25.
The phylogenetic tree maps inhibitors of related human kinases
against a single kinetoplastid isoform, illustrating the ancestral rela-
tionship of T. brucei kinases to multiple human homologues. These
human–kinetoplastid kinase clusters provide starting points for fur-
ther modes of action validation, with the caveat that many kinase
inhibitors inhibit multiple, distantly related enzymes26. In addition to
serine/threonine inhibitors kinases, several lipid kinases (phospha-
tidylinositol-kinases) were identified (Table 1). Lipid kinases also
have a much lower complement in kinetoplastids compared to
humans27, and could be important targets for either direct-acting
anti-parasite drugs or disrupters of host–pathogen interactions28.
Potential modes of action hypotheses for the chemical box com-
pounds were suggested against other kinetoplastid proteins, mainly
phosphosdiesterases (PDEs), cysteine peptidases and cytochromes
(CYPs) (Table 2). All these proteins have been previously proposed
as new kinetoplastid drug targets and some are under active invest-
igation. Phosphodiesterase C is conserved across Leishmania sp. and
Trypanosoma sp. where it is essential for disposal of cyclic nucleo-
tides29. Several PDE inhibitors have been tested against kinetoplas-
tids, in particular T. cruzi30 and T. brucei31. Kinetoplastid cysteine
peptidases are homologous to mammalian cathepsins B and L pep-
tidases and perform essential roles. T. brucei requires active cysteine
protease to deactivate the protective action of human apolipoprotein
LI32,33. Kinetoplastid cytochromes are also a growing area of new
drug development. CYP51 inhibition clears Chagas disease in mouse
models34, and ferric reductase, which has cytochrome P450 sequence
homology, is the primary mechanism of host iron uptake by T.
brucei35. Several recent papers highlight the large diversity of struc-
tures that can bind to CYP5136–38, suggesting that a wide range of
heterocyclic moieties can serve as a key pharmacophore binding to
the cytochrome metal group. The large number of potential metal-
binding pharmacophores in the kinetoplastid chemical boxes is strik-
Figure 2 | Histogram of assignment of positive compounds based on historical assay data and homology of human protein targets to kinetoplastid
genomes. Histograms are clustered by assays for Leishmania donovani (Ld), Trypanosoma brucei (Tb) and T. cruzi (Tc). The threshold above which
compound efficacy against specific human targets was considered significant was defined as pIC50$ 5 for inhibition or antagonist assays, and pEC50$ 5
for agonist, activation ormodulator assays (i.e. overall pXC50$ 5). Kinetoplastid homologs to human proteins were assigned based on BLASTP E-values
# 1.0e–05. Some compounds met the criteria for multiple human proteins (cross-hatched bars) while some kinetoplastid proteins had homology to
multiple human proteins (solid bars).
www.nature.com/scientificreports
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ing, i.e. 39 meta-substituted pyridyl compounds, 20 para-substituted
pyridyl compounds, and 20 imidazole-containing compounds.
There are also an unusually high number of methylene dioxy con-
taining compounds (28 of them). Although we could find no record
of this moiety being a key feature of parasite CYP51 inhibitors, and
indeed none of these were found to be T. cruzi CYP51 inhibitors, it
Table 1 | Examples of proposed kinetoplastid targets for kinases based on homology to mammalian proteins used in historical assay with
some examples compounds
Target class
Potential kinetoplastid targeta
No. of
chemotypes/
compounds Example structuresL. donovani
T. brucei (RNAi
phenotype)b T. cruzi
Ser/Thr kinases LDBPK_050390
LDBPK_071030
LDBPK_081250
LDBPK_100540
LDBPK_130280
LDBPK_150180
LDBPK_151630
LDBPK_160310
LDBPK_170440
LDBPK_170770
LDBPK_180270
LDBPK_181090
LDBPK_191480
LDBPK_200780
LDBPK_211320
LDBPK_211870
LDBPK_220770
LDBPK_242410
LDBPK_261710
LDBPK_272420
LDBPK_280550
LDBPK_292140
LDBPK_292830
LDBPK_300370
LDBPK_300620
LDBPK_303090
LDBPK_320270
LDBPK_331930
LDBPK_332420
LDBPK_340030
LDBPK_343750
LDBPK_344160
LDBPK_360600
LDBPK_360970
Tb927.9.4910
Tb927.9.11030
Tb927.9.14430
Tb927.10.460
Tb927.10.1070
Tb927.10.1910
Tb927.10.4990
Tb927.10.5140
Tb927.10.5310
Tb927.10.8420
Tb927.10.10350
Tb927.10.12040
Tb927.10.13010
Tb927.10.13490
Tb927.10.13780
Tb927.10.14420
Tb927.10.14780
Tb927.10.16030
Tb927.11.3140
Tb927.11.4470
Tb927.11.8220
Tb927.3.3190
Tb927.4.800
Tb927.4.2500
Tb927.4.3420 (S)
Tb927.4.3770
Tb927.5.790 (D)
Tb927.5.1650
Tb927.5.2820
Tb927.6.2250
Tb927.7.3580
Tb927.7.3650
Tb927.7.6220 (A)
Tb927.7.6310
Tb927.8.870
Tb927.8.3550
Tb927.8.5730 (A)
Tb927.8.5950
Tb927.11.14070
Tb927.1.1000
Tc00.1047053398235.10
Tc00.1047053506007.40
Tc00.1047053504181.40
Tc00.1047053504001.6
Tc00.1047053508041.10
Tc00.1047053503953.30
Tc00.1047053508917.10
Tc00.1047053510409.10
Tc00.1047053511299.70
Tc00.1047053510733.10
Tc00.1047053511269.50
Tc00.1047053511633.70
Tc00.1047053506477.60
Tc00.1047053510407.9
Tc00.1047053509607.70
Tc00.1047053509065.180
Tc00.1047053509941.120
Tc00.1047053508817.80
Tc00.1047053508965.60
Tc00.1047053503823.169
Tc00.1047053510055.160
Tc00.1047053509167.190
Tc00.1047053510759.40
Tc00.1047053509007.60
Tc00.1047053509937.130
Tc00.1047053510329.210
Tc00.1047053511127.320
Tc00.1047053508461.280
Tc00.1047053511277.140
Tc00.1047053508153.400
Tc00.1047053506825.180
Tc00.1047053507063.130
Tc00.1047053506679.80
Tc00.1047053508909.330
Tc00.1047053507993.80
Tc00.1047053511283.280
29/78 2,4-diamino-pyrimidine series
(16 compounds)
TCMDC-143365
2-amino-4-aryl pyrimidine series
(11 compounds)
TCMDC-143634
Amino-heterocycle-pyrimidine
series (7 compounds)
TCMDC-143341
Azaindole series (5 compounds)
TCMDC-143234
Thiophene benzimidazole series
(4 compounds)
TCMDC-143596
Phosphatidylinositol-kinases LDBPK_291550
LDBPK_242090
LDBPK_140020
LDBPK_044320
Tb927.3.4020
Tb927.4.1140
Tb927.8.6210
Tc00.1047053510003.30
Tc00.1047053510167.10
2/5
TCMDC-143352
aGene loci identifiers given in descending order for Leishmania donovani (LDBPK), Trypanosoma brucei (Tb) and T. cruzi (Tc).
bRNAi phenotypes scored for Arrest (A), Slow (S) and Death (D) in Trypanosoma brucei according to Table 1 in Jones et al.22.
www.nature.com/scientificreports
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does interact with human cytochrome P450s. Although it is unlikely
that all compounds with these potential metal interacting moieties
are working through a parasite cytochrome, it is an area that should
be explored in more depth.
Another functional group that appears at an unusually high rate
(62 compounds) is the nitro-substituted aryl group, including nitro-
pyrazoles, nitro-triazoles, nitro-furans, nitro-thiophenes, and nitro-
benzenes. This is perhaps expected as nifurtimox and benznidazole
are nitro-substituted aromatics used clinically for Chagas disease.
These two drugs are substrates for a parasite type I nitroreductase
and are converted into metabolites toxic to the parasite39. There is no
mammalian homologue to this target, suggesting a potentially useful
therapeutic window. There has been increased interest in nitro drugs
to treat these parasitic diseases40, and the wide range of nitro-aro-
matic compounds present in these sets facilitates further substrate
selectivity studies.
For those compounds putatively associated with protein targets,
we developed a preliminary systems biology network view of tar-
geted pathways based on all known KEGG pathways for the kineto-
plastid species41,42. The analysis included compounds with both
human and kinetoplastid putative protein targets, i.e. 31, 48 and
62 compounds were analyzed for T. cruzi, T. brucei and L. donovani,
respectively. These compounds are associated to 33 proteins in these
parasites. Description of these proteins was taken from the NCBI
Gene database (http://www.ncbi.nlm.nih.gov/gene). Pathway inter-
actions were mapped for the individual kinetoplastid species and as a
combined three species map (Figure 4).
Some additional predictions of homologous protein targets were
included in this map, for which there were fewer compounds. A key
caveat for these analyses is that the kinetoplastid KEGG reference
pathways are incomplete41. For example, there are only 91 known
pathways for T. brucei, versus 288 for humans. Thus, not all kineto-
plastid proteins were associated with pathways. However, the total
network still included 42 compounds for T. brucei (68% of all com-
pounds analyzed), 16 (52%) for T. cruzi, and 28 (58%) for L. dono-
vani. Other compounds target proteins with no known pathways.
Figure 3 | Neighbor-joining phylogenetic tree of combined human and Trypanosoma brucei str. 927 kinomes. Human kinase targets with putative
compounds are colored and prefixed (T_red); all human kinases are colored black. T. brucei kinases are colored and prefixed for the RNAi phenotypes
death (D_blue), arrest (A_dark green) or slow (S_orange) according to Table 1 in Jones et al.22. All other T. brucei kinases are colored violet. A few key
clusters of human target and essential T. brucei kinases are labeled. The size and color of circles on the nodes represent support in 1000 bootstrap
replicates.
www.nature.com/scientificreports
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Table 2 | Some examples of proposed kinetoplastid targets for non-kinases based on homology to mammalian proteins used in historical
assay with some examples compounds
Target class
Potential kinetoplastid target
No. of chemotypes/
compounds Example structuresProtein Gene locia
Other enzyme Phosphosdiestearase LDBPK_181100
Tc00.1047053511269.40
Tc00.1047053509805.20
Tb10.389.0510
3/4
TCMDC-143547
TCMDC-143248
Proteases Cysteine peptidases
A (CBA) or C (CPC)
LDBPK_290860 (CPC)
LDBPK_191460 (CBA)
Tb927.6.560 (CPC)
Tb927.6.960 (precursor)
Tb927.6.1020 (precursor)
Tc00.1047053510535.
100 (CPC)
3/6
TCMDC-143238
TCMDC-143390
Cytochromes Ferric reductase
(cytochrome homology)
LDBPK_301630
Tb11.02.1990
Tc00.1047053507665.30
5/5
TCMDC-143560 (also a kinase
inhibitor scaffold)
TCMDC-143603
Cytochrome P450 and
lanosterol
14-alpha-demethylase
LDBPK_270090
LDBPK_343110
Tb03.27F10.920
Tb11.02.4080
Tc00.1047053509231.10
Tc00.1047053509719.40
Tc00.1047053510101.50
24/44
TCMDC-143376
TCMDC-143433
www.nature.com/scientificreports
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Although there were some species-specific pathways for T. brucei (n
5 4), T. cruzi (n 5 3) and L. donovani (n 5 1), the majority of
hypothesized targets (and compounds) could be assigned pathways
common to all three parasites, including ‘biosynthesis of secondary
metabolites’, ‘metabolic pathways’, ‘phosphatidylinositol signaling
system (and metabolism)’, ‘regulation of autophagy’, ‘nicotinate and
nicotinamide metabolism’ and ‘steroid biosynthesis’. Interestingly,
there were some proteins, e.g. silent information regulator 2 (XP
816094, XP 845793 and CBZ34909 for T. cruzi, T. brucei and L.
donovani, respectively), with the same biological description and
pathway in all three species. The compounds targeting these proteins
may, therefore, disrupt this pathway in the same manner.
There were also several compounds associated with human pro-
teins with no known homologs in kinetoplastids, such as G-coupled
protein receptors (GPCRs), nuclear receptors, ion channels and
transporters. These compounds potentially act on evolutionarily
unrelated targets or essential proteins that, although structurally
and functionally similar to the human targets, have no significant
primary amino acid homology. Importantly, two assays in this study
used parasites cultured in human host cells (L. donovani in macro-
phages and T. cruzi infecting fibroblasts). Thus, modulation of host–
pathogen interactions could be an indirect mode of action for some
compounds (with either homologous or non-homologous human
targets). For example, L. donovani potentially modulates the cAMP
signaling pathways mediated by the GPCR EP2 or PTGER243.
Disruptors of host–parasite interactions could lead to novel anti-
kinetoplastid therapeutic strategies, less susceptible to the selection
pressures which drive drug resistance in the parasite.
This paper reports for the first time the outcome from a parallel
high throughput screening of a pharma compound collection (1.8
million compounds) against the three most relevant Leishmania and
Trypanosoma parasites causative of human disease. Three corres-
ponding kinetoplastid chemical boxes were identified, encompassing
a wide variety of potential targets, such as kinases, proteases, and
cytochromes as well as potential host-pathogen interaction targets.
The outcomes of this research are publically disclosed in full, and
physical samples of the three kinetoplastid chemical boxes are avail-
able to collaborators upon request. We expect this information will
enable the scientific community to address relevant research questions
and seed lead discovery programs that eventually deliver innovative
treatments for these important, but neglected diseases.
Methods
Parasites and mammalian cell cultures. LLC-MK2 cells (green monkey kidney
epithelial cells) were purchased from the European Cell Cultures Collection (ECACC
reference 85062804) and used to expand the T. cruzi parasite population. NIH-3T3
cells (mouse endothelial fibroblasts) weremade available by GSK-Biological Reagents
and Assay Development Department (BRAD, Stevenage, UK). H9c2 (rat
cardiomyocytes) were purchased at the European Cell Cultures Collection (ECACC,
Salisbury, UK).T. cruzi parasites from the Tulahuen strain expressing b-galactosidase
were kindly provided by Dr. Buckner (University of Washington, Seattle, USA;
Buckner et al., 1996). Parasites were maintained in culture by weekly infection of
LLC-MK2 cells. Trypomastigote forms were obtained from the supernatants of LLC-
MK2 infected cultures harvested between days 5 and 9 of infection, as described
elsewhere10. THP-1 cells (human monocytic leukemia) were made available by GSK-
Biological Reagents and Assay Development Department (BRAD, Stevenage, UK).
LdBOB axenic amastigotes expressing eGFP were kindly provided by Manu de
Rycker fromDundee University.Trypanosoma brucei brucei bloodstream form Lister
427, was provided by Miguel Navarro from Instituto Lopez Neyra (Consejo Superior
de Investigaciones Cientificas, Granada, Spain). HepG2 (human hepatoma) was
provided by GSK-Biological Reagents and Assay Development Department (BRAD,
Stevenage, UK).
Leishmania donovani. Primary growth inhibition assay: Assay plates (1536-well) were
prepared by adding 30 nL per well of compound. For single shot assay, the final
compound concentration was 5 mM. For potency determinations, eleven-point one
in three dilution curves were generated with a top concentration of 50 mM. The assay
was adapted from de Rycker et al.7. Briefly, eGFP LdBOB axenic amastigotes were
harvested, fixed and counted in a CASY cell counter (Roche-Applied Science). A final
concentration of 1.5 3 105 cells per well were prepared in amastigote media con-
taining 500 U/mL penicillin/streptomycin (InvitrogenTM) and 6 mL was dispensed to
each experimental well using aMultidrop Combi dispenser (Thermo Scientific). 6 mL
of assay media was dispensed to control columns used as reference for 100% com-
pound response. Following incubation for 72 h at 37uC, 5% CO2, 2 mL of resazurin
was added to each well at a final concentration of 0.5 mM in phosphate buffered
saline (PBS) with IGEPAL (Sigma-Aldrich), 0.05% (v/v). The plates were incubated
for 4 h at room temperature and resorufin fluorescence was detected using a
PerkinElmer EnVision plate reader with excitation at 528 nm and emission at
590 nm.
Intra-macrophage L. donovani assay: Assay plates (384-well) were prepared by
adding 250 nL of compound to each well. For single shot assay, the final compound
concentration was 5 mM. For potency determinations, eleven-point one in three
dilution curves were generated with a top concentration of 50 mM. The assay was
adapted from de Rycker et al.7. Briefly, THP-1 cells were grown previously in
CELLMASTER roller bottles (Greiner cat. # 680048) at a concentration of 9 3
105 cells/mL for 72 h. The cells were monitored using an optical microscope and
counted using a CASY cell counter. Then they were differentiated in 225 cm3 T-
Table 2 | Continued
Target class
Potential kinetoplastid target
No. of chemotypes/
compounds Example structuresProtein Gene locia
TCMDC-142497
TCMDC-143182
aGene loci identifiers given in descending order for Leishmania donovani (LDBPK), Trypanosoma brucei (Tb) and T. cruzi (Tc).
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Figure 4 | Pathway network analysis of combined and individual kinetoplastid target hypotheses. Pathways were assigned using KEGG and visualized
using Cytoscape42. Proteins of three species are grouped and colored according to general functional groups (kinases, proteases, other enzymes and
cytochromes).
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FLASK in the presence of 30 nM of PMA (phorbol 12-myristate 13-acetate) (Sigma-
Aldrich) at a final concentration of 63 105 cells/mL. Following incubation for 24 h at
37uC, 5% CO2, cell differentiation were visually confirmed using an optical micro-
scope. Cells were washed twice using cell culture media. Cells were infected using
eGFP LdBOB axenic amastigotes at a multiplicity of infection of 10 (i.e. 6 3
106 parasites/mL) in the T-FLASK containing differentiated THP-1 cells. Each T-
FLASK was incubated overnight and the remaining parasite was removed washing
three times with sterile DPBS. The infected cells was harvested by treatment with
0.05% (w/v) trypsin plus 0.48 mM EDTA for 5 min and an aliquot was fixed and
counted in a CASY cell counter. A cell preparation with a final concentration of 1.63
105 cells/mL was prepared in assaymedia consisting of RPMI (InvitrogenTM), 2% FBS
(Gibco) and 25 mM sodium bicabonate (InvitrogenTM) containing 30 nM of PMA.
Infected cells were plated onto assay plates containing compounds (3000 cells/well,
50 mL) using a Multidrop Combi dispenser. Amphotericin B (SigmaAldrich) was
used as positive control of 100% compound response and was prepared by diluting
the compound in an aliquot of infected cells for a final concentration of 2 mM.Treated
cells were dispensed into the control column using a Multidrop Combi dispenser.
Plates were incubated for 96 h at 37uC, 5% CO2 and then fixed with 4% (v/v)
formaldehyde-PBS for 30 min at room temperature. After fixation, the wells were
washed twice with 100 mL PBS using an EL406 multi well platewasher (BioTek),
stained with 10 mg/mLDAPI in PBS plus 0.1% (v/v) Triton X-100 for 30 min at room
temperature, and washed twice with 50 mL PBS. Finally, 50 mL of PBS was added to
each well and the plates were sealed and read on a high-content microscope (Opera
QEHS) using a 20x objective, 3 fields per well. Two exposure images were taken for
each well using 405 nm and 488 nm laser excitation. Automated image analysis was
performed with a script developed on AcapellaHHigh Content Imaging and Analysis
Software (PerkinElmer). THP-1 cell count, average number of amastigotes per
macrophage and percent of infected cells were reported for each well.
Trypanosoma cruzi. Primary growth inhibition assay: The assay developed was
adapted from the one previously described by Bettiol, et al.10. Active compounds in
this assay format will target intracellular T. cruzi amastigotes growing in NIH-3T3
murine fibroblasts, though to a smaller extent they may also target free swimming
trypomastigotes and/or the host–parasite interactions required for the parasite
invasion. The assay was performed in tissue culture surface treated 1536 well plates.
This assay was run at single shot at 5 mM compound concentration per well. The
biological reagents consisted of NIH-3T3 host cells and trypomastigotes parasitic
cells; both cell types were set to a 3.3 3 105 cells/mL dilution in assay DMEM by
means of a CASY cell counter device using a 60 mm capillary. 6 mL of the mixture
were dispensed per well (about 1 3 103 host-cells and 1 3 103 parasites) with a
Multidrop Combi dispenser. Previously, a solution of 1.673 105 trypomastigotes per
mL in assay DMEM had been prepared and 6 mL per well dispensed in the allotted
control columns that defined 100% inhibition. The 0% inhibition of parasitic growth
control was obtained by leaving the assaymixture untreated in its corresponding plate
columns. In all wells, the percentage of DMSO never exceeded 0.5%. Plates incubated
for four days at 37uC, 5% CO2. The substrate used for the assay fluorescence intensity
(FLINT) readout was resorufin-b-D-galactopiranoside (Sigma-Aldrich) at 5 mM per
well. It was diluted in PBS supplemented with the soft detergent Igepal (Fluka) as
described elsewhere44. Upon addition to the plates, the substrate solution was incu-
bated for 4 h at room temperature and the signal read with the EnVision microtiter
plate reader (Perkin-Elmer) using the corresponding set of filters (excitation/emis-
sion at 531/595 nm).
Trypanosoma cruzi intracellular imaging assay: This intracellular assay in H9c2
(rat cardiomyocyte) cells was as per Alonso-Padilla, et al.11. Briefly, H9c2 cells were
seeded in T-225 flasks (225 cm2 culture surface; Corning Inc., NY, USA) in DMEM-
10% FBS for 4 h to allow attachment. Cells were then washed once with PBS before
infection. T. cruzi trypomastigotes, collected at days 5 to 8 after infection from LLC-
MK2 parasite infected cultures, were allowed to swim out for 4 h at 37uC from a
centrifuged pellet (2,500 rpm/10 min/room temperature). Trypomastigotes were
then collected and counted in a CASY Cell Counter. Trypomastigotes, in supple-
mented DMEM, were added to H9c2 cultures in a multiplicity of infection of 1 and
incubated for 18 h. Cells were washed once with PBS before incubation of the infected
H9c2 monolayer with trypsin (Life-Technologies) to detach cells from the flask. Cells
were counted in aCASYCell Counter using a 150 mmcapillary and their density set at
53 104 cells per mL in supplemented assay DMEM. Infected H9c2 were dispensed
into 384-well poly-lysine coated assay plates at 50 mL per well using a Multidrop
Combi dispenser. After seeding them, the plates were incubated at 37uC, 5% CO2 for
72 h. Cultures were then fixed and stained by addition of 50 mL of a solution con-
taining 8% formaldehyde and 4 mM DRAQ5 DNA dye (BioStatus, UK) per well.
Plates were kept light-protected and imaged one hour later in a Perkin-Elmer Opera
microscope using a 20x air objective (NA 0.4) and the following acquisition set: a
635 nm laser excitation line and a 690/50 emission detection filter for DRAQ5
detection. Five images were collected per well for reliable statistical analysis.
Automated image analysis was performed with a script developed on AcapellaHHigh
Content Imaging and Analysis Software (PerkinElmer). Three outputs were provided
for each sample well: (1) number of host cells nuclei to determine drug-related
cytotoxicity; (2) number of amastigotes per cell as infection level measurement; and
(3) percentage of infected cells per well as a second infection marker.
Trypanosoma brucei. Primary growth inhibition assay: This resazurin (Alamar Blue)
fluorescent whole cell viability assay was based on that of Sykes & Avery14. Assay
plates (1536 well) were prepared by dispensing 25 nL of compound solution per well
using an Echo acoustic dispenser (Labcyte). For single shot assays the final compound
concentration was 4.2 mM. For potency determinations, eleven-point one in three
dilution curves were generated and the top concentration was 42 mM. For control
samples, DMSOwas pre-dispensed. T. brucei Lister strain 427was cultured, harvested
and counted in a CASY cell counter. A parasite suspension was prepared at a final
concentration of 53 104 cells/mL in complete HMI9 medium and 6 mL dispensed to
all wells containing compounds using a Multidrop Combi dispenser. 6 mL of HMI9
media supplemented with 0.4% DMSO was dispensed to C2 wells. After 48 h of
incubation at 37uC, 5% CO2, plates were tempered for 10 min at room temperature
before addition of 2 mL of resazurin to each well at a final concentration of 50 mM in
PBS. Plates were incubated for 2 h at room temperature and resorufin fluorescence
was determined using a PerkinElmer ViewLux plate reader (excitation at 528 nm and
emission at 590 nm).
Ttrypanosoma brucei growth inhibition luminescent assay: An ATP-based
luminescence assay was run as confirmatory probe for the selected compounds in
dose–response format, as per Sykes & Avery16. Pre-dispensed plates (1536 well) were
prepared as described above for the fluorescence assay. T. brucei cultures were har-
vested and counted in a CASY cell counter. A parasite suspension was prepared at a
final concentration of 5 3 104 cells/mL in complete HMI9 medium and 6 mL was
dispensed to all wells containing compounds using a Multidrop Combi dispenser.
6 mL of HMI9 media with 0.4% DMSO were dispensed to control columns. Plates
were incubated for 24 h at 37uC, 5% CO2 then tempered for 10 min at room tem-
perature. ATP content was quantified by adding 4 mL of CellTiter-GloH Reagent
(Promega) according to the manufacturer’s instructions. Luminescence was mea-
sured using a ViewLux.
HepG2 cytotoxicity assay.Actively growingHepG2 cells were removed from aT-175
TC flask using 5 mL Eagle’s MEM (containing 10% FBS, 1% NEAA, 1% penicillin/
streptomycin) and dispersed in the medium by repeated pipetting. Seeding density
was checked to ensure that new mono-layers were not more than 50% confluent at
the time of harvesting. Cell suspension was added to 500 mL of the samemedium at a
final density of 1.23 105 cells/mL. This cell suspension was dispensed (25 mL, 3000
cells per well) into 384-well clear-bottom plates using a Multidrop Combi dispenser.
Prior to addition of the cell suspension, the screening compounds (250 nL) were pre-
dispensed into the plates with an EchoH liquid handler. Plates were incubated for 48 h
at 37uC, 5% CO2. After incubation, plates equilibrated at room temperature for
30 min before proceeding to develop the luminescent signal. The signal developer,
CellTiter-GloH Reagent, was allowed to equilibrate at room temperature for 30 min
and added to the plates (25 mL per well) using a Multidrop Combi dispenser. Plates
were left for 10 min at room temperature for stabilization and then read using a
ViewLux.
NIH-3T3 cytotoxicity. Since T. cruzi is an obligatory intracellular parasite, those
compounds that affect the host-cells viability would also be reported as anti-parasite
hits by the previously described phenotypic assay. Therefore, a complementary assay
was developed to determine the hits for NIH-3T3 cytotoxicity and/or their anti-T.
cruzi specificity. Tissue culture surface treated assay plates (1536 well) were used.
5 mL of a 23 105 cells per mL solution were dispensed per well (,103 host cells), into
plates already containing compounds which had been pre-dispensed. The 100% cells
survival control was determined exposing the host-cells to a 0.5% DMSO
concentration, whereas the 100% toxicity control was achieved by seeding the cells in
presence of Amphotericin B at 50 mM. Plates were incubated for four days at 37uC,
5% CO2. The assay readout was developed by addition of 5 mL of CellTiter-GloH
Reagent following the manufacturer’s instructions. Luminiscence was measured
using a ViewLux.
Data analysis. Data were normalized to percent of biological response by using
positive (i.e. highest response achieved by a chemical tool compound, RCtrl2) or
negative (i.e. lowest response achieved in the absence of any testing compound, RCtrl1)
controls by using the following equation (Equation 1):
%Response~
RCtrl1{Rxj j
RCtrl1{RCtrl2j jj j
:100
where Rx is the assay response measured for the compound X. RCtrl1 and RCtrl2 are
calculated as the average of replicates in the same microtiter plate where the
compound X is tested.
Assay performance statistics, such as signal to background ratio, Z9 and robust 3SD
activity cutoff were calculated using templates in ActivityBase XE (IDBS, Guilford,
Surrey, UK). Hit population analysis and visualization were conducted using Spotfire
DecisionSite (Spotfire, Inc., Somerville, Massachusetts). pIC50 values were obtained
using the ActivityBase XE nonlinear regression function in the full curve analysis
bundle.
Selection criteria for the anti-kinetoplastid chemical boxes. In the case of L.
donovani, this corresponded to a pIC50. 5 in the amastigote per macrophage ratio
(AM/MAC) or in the percentage of infected cells (INF), a ratio of IC50AM/MAC/
IC50MAC. 5, and a ratio of IC50AM/MAC/IC50HepG2. 10. In the case of T. cruzi, this
comprised a pIC50. 5 in theT. cruzi primary assay, a pIC50, 5 in theHepG2 assay, a
pIC50, 5 in the NIH-3T3 host cell assay, a ratio of IC50Tc/IC50HepG2. 10, and a ratio
of IC50Tc/IC503T3. 10. In the case of T. brucei this corresponded to a pIC50. 6 in the
fluorescent (primary) and luminescent (secondary) T. brucei whole cell assays and
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selectivity indexes . 10 for HepG2. In addition, all the dose–response curves were
inspected and compounds were disregarded in case of aberrant fit or bizarre shape
(i.e. low slope or low maximum asymptote).
Bioinformatics analysis. In order to develop modes of action hypotheses, GSK
proprietary compound screening databases were queried for historical assay data
associated with active compounds from each of the three kinetoplastid species
screens. Themajority of these screens were against human protein targets. Thresholds
for significant compound efficacy against specific human targets were defined as
pIC50$ 5 for inhibition or antagonist assays, and pEC50$ 5 for agonist, activation or
modulator assays (i.e. overall pXC50 $ 5). Human target proteins were binned by
screen according to their compound hit against L. donovani (139 human proteins), T.
brucei (161 human proteins) and T. cruzi (110 human proteins). The human target
protein sequences were used as BLASTP19 queries to search for homologs in the
respective translated reference genomes for L. donovani strain BPK282A145, T. brucei
strain 927/4 GUTat10.146 and T. cruzi strain CL Brener47, with a cut-off E-value #
1.0e-05 then subsequently confirmed by reciprocal searches against the human
genome. A combined kinome phylogenetic tree was reconstructed using all annotated
human kinases as well as T. cruzi strain 927 kinases annotated by Interpro kinase
queries of TriTrypDB4 or reported by Urbaniak et al.20. RNAi kinase phenotypes in T.
brucei strain 927 were annotated as death, slow or arrest according to Table 1 in Jones
et al.22. Initial multiple sequence alignments were performed using the program
CLUSTALW v1.748 with default settings and subsequently, refined manually using
the program JALVIEW49. Residues that could not be unambiguously aligned or that
contained insertions or deletions were removed from the multiple sequence
alignment prior to phylogenetic analysis. The final kinase multiple sequence
alignment was 114 amino acids in length and included a combined total of 657 human
and T. brucei kinases. We reconstructed phylogenetic trees using distance neighbor-
joining (NJ) using the JTT option as implemented in the software MEGA650. All trees
were visualized using the program FigTree v1.4.0 (http://tree.bio.ed.ac.uk/software/
figtree). Network analysis was done using KEGG reference pathways41 for individual
parasites and general description of all analyzed genes were taken from the NCBI
Gene database (http://www.ncbi.nlm.nih.gov/gene). Cytoscape was used for
visualization of the compound-protein-pathway networks42.
Biosafety. Experimental work with live L. donovani or T. cruzi cells were carried out
following standard operating procedures in compliance with biosafety level 3
regulations (BSL3). Work with T. brucei was developed under biosafety level 2
procedures. HepG2 and THP-1 cells were treated according to GSK policies for
management of human biological samples
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